CAN1012 Combined With PD-1 in Patients With Solid Tumors
This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic Advanced Solid Tumors who have exhausted options for standard of care therapy.
Advanced Solid Tumor
DRUG: CAN1012
Safety and tolerability, Safety and tolerability as determined by assessing dose limiting toxicities, the maximum tolerated dose or maximal assessed dose per protocol in combination with toripalimab (anti-PD-1) with patients., 1 year
To determine the MTD and or RP2D of CAN1012 Combined with PD-1, Monitor a tumor response to the combination therapy according to RECIST 1.1 or iRECIST 1.1 as appropriate., Monitor a tumor response to the combination therapy according to RECIST 1.1 or iRECIST 1.1 as appropriate.|To determine the Pharmacokinetics of CAN1012 Combined with PD-1, Determine CAN1012 concentrations in plasma after IT administration., 1 year
The scope of the study is to evaluate the safety of the combination therapy of CAN1012 and PD-1 in human, study its efficacy and pharmacokinetics profiles, as well as explore its pharmacodynamic effects and biomarkers.